<DOC>
	<DOC>NCT02567656</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, PK and efficacy of RP6530, a dual PI3K delta/gamma inhibitor in patients with relapsed and refractory T-cell Lymphoma.</brief_summary>
	<brief_title>Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma</brief_title>
	<detailed_description>Safety: Treatment-Emergent AE; Treatment-Related AE, SAE and Clinical significant AE; Dose Limiting Toxicities (DLT). PK: Peak Plasma Concentration (Cmax), Area under the plasma concentration versus time curve (AUC), Time of Maximum concentration observed (Tmax). Efficacy: Overall Response Rate (ORR), Progression Free Survival (PFS), Overall Survival (OS) and Duration of Response.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, T-Cell</mesh_term>
	<mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
	<mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
	<criteria>Refractory to or relapsed after at least 1 prior treatment line. ECOG performance status ≤2 Patients must be ≥18 years of age Able to give a written informed consent. Any cancer therapy in the last 3 weeks or limited palliative radiation &lt;2 weeks Patients with HBV, HCV or HIV infection Previous therapy with GS1101 (CAL101, Idelalisib), IPI145 (Duvelisib), TGR1202 or any drug that specifically inhibits PI3K/ mTOR (including temsirolimus, everolimus), AKT or BTK Inhibitor (including Ibrutinib) in last 6 months Patients on immunosuppressive therapy including systemic corticosteroids. Patients with known history of liver disorders. Patients with uncontrolled Diabetes Type I or Type II Any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study. Women who are pregnant or lactating.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>CTCL</keyword>
	<keyword>PTCL</keyword>
	<keyword>RP6530</keyword>
</DOC>